Jon Travers

1.3k total citations
23 papers, 659 citations indexed

About

Jon Travers is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Jon Travers has authored 23 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 9 papers in Cell Biology. Recurrent topics in Jon Travers's work include Microtubule and mitosis dynamics (9 papers), Acute Myeloid Leukemia Research (4 papers) and Protein Degradation and Inhibitors (4 papers). Jon Travers is often cited by papers focused on Microtubule and mitosis dynamics (9 papers), Acute Myeloid Leukemia Research (4 papers) and Protein Degradation and Inhibitors (4 papers). Jon Travers collaborates with scholars based in United Kingdom, United States and Australia. Jon Travers's co-authors include Paul Workman, Swee Y. Sharp, Stephen P. Jackson, Carol V. Robinson, Satpal S. Jhujh, Viji M. Draviam, Julia Coates, Tom L. Blundell, Andrew N. Blackford and Shahid Mehmood and has published in prestigious journals such as Nature, Science and Nature Communications.

In The Last Decade

Jon Travers

21 papers receiving 651 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon Travers United Kingdom 9 501 270 80 64 63 23 659
Edward C. Stites United States 15 574 1.1× 227 0.8× 84 1.1× 48 0.8× 94 1.5× 36 772
Madhu Lal‐Nag United States 13 392 0.8× 167 0.6× 148 1.9× 50 0.8× 70 1.1× 19 778
Heriberto Bruzzoni‐Giovanelli France 15 570 1.1× 281 1.0× 69 0.9× 145 2.3× 54 0.9× 23 932
Patricia Jaaks Germany 11 474 0.9× 149 0.6× 129 1.6× 48 0.8× 76 1.2× 14 650
C. Moeder United States 8 393 0.8× 225 0.8× 111 1.4× 63 1.0× 30 0.5× 9 584
Melanie L. Bailey Canada 10 669 1.3× 307 1.1× 121 1.5× 108 1.7× 43 0.7× 14 768
Bram Thijssen Netherlands 11 539 1.1× 203 0.8× 96 1.2× 100 1.6× 88 1.4× 24 825
Keelan Z. Guiley United States 11 604 1.2× 273 1.0× 123 1.5× 39 0.6× 26 0.4× 15 804
Stacey L. Hembruff United States 16 583 1.2× 351 1.3× 149 1.9× 99 1.5× 37 0.6× 23 890
Prerna Malaney United States 9 491 1.0× 156 0.6× 114 1.4× 70 1.1× 19 0.3× 19 718

Countries citing papers authored by Jon Travers

Since Specialization
Citations

This map shows the geographic impact of Jon Travers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Travers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Travers more than expected).

Fields of papers citing papers by Jon Travers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Travers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Travers. The network helps show where Jon Travers may publish in the future.

Co-authorship network of co-authors of Jon Travers

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Travers. A scholar is included among the top collaborators of Jon Travers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Travers. Jon Travers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chatterjee, Saptarshi, Mathew V. Jones, Yaowu He, et al.. (2025). Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells. Cell Death and Disease. 16(1). 7–7. 2 indexed citations
2.
Bonfim‐Melo, Alexis, Yoon Lim, Yaowu He, et al.. (2024). Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition. Cell Death and Disease. 15(11). 810–810. 4 indexed citations
3.
Ramkumar, Kavya, Azusa Tanimoto, Carminia M. Della Corte, et al.. (2023). Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer. Clinical Cancer Research. 29(16). 3237–3249. 14 indexed citations
4.
Chou, David B., Christos Kyprianou, Lucy R. O’Sullivan, et al.. (2022). Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors. Nature Communications. 13(1). 6021–6021. 4 indexed citations
5.
Harper, James A., Shannon Burke, Jon Travers, et al.. (2021). Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. Molecular Cancer Therapeutics. 20(9). 1723–1734. 10 indexed citations
6.
Casado, Pedro, Maruan Hijazi, Nosheen Akhtar, et al.. (2021). Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. Nature Communications. 12(1). 1850–1850. 84 indexed citations
7.
Bertrán-Alamillo, Jordi, Edmund H. Wilkes, Hilary Lewis, et al.. (2021). Abstract 1107: Precision phosphoproteomic analysis in Chr22q11.2 amplified NSCLC cells reveals distinct signaling corruption and response to Aurora kinase B inhibition. Cancer Research. 81(13_Supplement). 1107–1107.
8.
Corte, Carminia Maria Della, Robert J. Cardnell, Li Shen, et al.. (2019). Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer. Annals of Oncology. 30. v716–v716. 4 indexed citations
9.
Brown, Fiona C., Jelena Urosevic, Urszula M. Polanska, et al.. (2019). Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML. Blood. 134(Supplement_1). 3930–3930.
10.
Donnellan, William B., Ehab Atallah, Adam S. Asch, et al.. (2019). A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy. Blood. 134(Supplement_1). 3919–3919. 4 indexed citations
11.
Ghosh, Srimoyee, Geeta Sharma, Jon Travers, et al.. (2018). TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo. Molecular Cancer Therapeutics. 18(3). 632–641. 50 indexed citations
12.
13.
Harper, James A., Jon Travers, Shannon Burke, et al.. (2016). Abstract 2234: Exploring the oncolytic potential of Newcastle Disease Virus. Cancer Research. 76(14_Supplement). 2234–2234. 1 indexed citations
14.
Ochi, Takashi, Andrew N. Blackford, Julia Coates, et al.. (2015). PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair. Science. 347(6218). 185–188. 237 indexed citations
15.
Gill, Sonja J., Jon Travers, Syd Barthorpe, et al.. (2015). Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma. PLoS ONE. 10(10). e0140988–e0140988. 62 indexed citations
16.
Carroll, Danielle, James A. Harper, Shannon Burke, et al.. (2015). Abstract 5334: Oncolytic Newcastle disease virus: armed but not dangerous. Cancer Research. 75(15_Supplement). 5334–5334. 1 indexed citations
17.
Couty, S., Isaac M. Westwood, Andrew Kalusa, et al.. (2013). The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget. 4(10). 1647–1661. 17 indexed citations
18.
Travers, Jon, Swee Y. Sharp, & Paul Workman. (2011). HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discovery Today. 17(5-6). 242–252. 84 indexed citations
19.
Travers, Jon, Julian Blagg, & Paul Workman. (2011). Targeting leukemia on the DOT. Nature Chemical Biology. 7(10). 663–665. 5 indexed citations
20.
Rayter, Sydonia, Richard Elliott, Jon Travers, et al.. (2007). A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 27(8). 1036–1044. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward C. Stites Breakdown of academic impact, for papers by Madhu Lal‐Nag Breakdown of academic impact, for papers by Heriberto Bruzzoni‐Giovanelli Breakdown of academic impact, for papers by Patricia Jaaks Breakdown of academic impact, for papers by C. Moeder Breakdown of academic impact, for papers by Melanie L. Bailey Breakdown of academic impact, for papers by Bram Thijssen Breakdown of academic impact, for papers by Keelan Z. Guiley Breakdown of academic impact, for papers by Stacey L. Hembruff Breakdown of academic impact, for papers by Prerna Malaney
Rankless by CCL
2026